| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/09/2024 | 14:15 | PR Newswire (US) | Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 13/09/2024 | 14:00 | Business Wire | Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 03/09/2024 | 14:30 | Business Wire | Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 27/08/2024 | 23:00 | Business Wire | Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 13/08/2024 | 13:54 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 05/08/2024 | 22:50 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 05/08/2024 | 22:01 | Business Wire | Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 01/08/2024 | 22:01 | Business Wire | Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 19/07/2024 | 01:30 | Business Wire | Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 17/07/2024 | 23:27 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 01/07/2024 | 22:01 | Business Wire | Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 20/06/2024 | 14:00 | Business Wire | Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 19/06/2024 | 03:01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 07/06/2024 | 16:30 | Business Wire | Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 28/05/2024 | 12:30 | Business Wire | Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 22/05/2024 | 13:00 | GlobeNewswire Inc. | Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 20/05/2024 | 14:30 | PR Newswire (US) | Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 20/05/2024 | 14:30 | Business Wire | Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 08/05/2024 | 22:01 | Business Wire | Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 25/04/2024 | 22:01 | Business Wire | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 07/03/2024 | 22:01 | Business Wire | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 26/02/2024 | 15:00 | Business Wire | Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 22/02/2024 | 14:30 | Business Wire | Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 20/02/2024 | 15:00 | Business Wire | Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 05/02/2024 | 14:30 | PR Newswire (US) | New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 21/12/2023 | 14:00 | PR Newswire (US) | CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 21/12/2023 | 14:00 | Business Wire | CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 04/12/2023 | 14:30 | Business Wire | Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 28/11/2023 | 14:05 | PR Newswire (US) | Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 28/11/2023 | 14:00 | Business Wire | Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |